$DMTKQ
DermTech Inc Stock $dmtkq

$dmtkq Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000165194422000054 Filed on November 03, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q4
Revenue	$2.994M	$3.573M	$3.165M
YoY Change	-5.4%	17.92%	49.29%
Cost Of Revenue	$3.350M	$3.694M	$3.040M
YoY Change	10.2%	27.47%	75.72%
Gross Profit	-$356.0K	-$121.0K	$125.0K
YoY Change	-384.8%	-191.67%	-68.75%
Gross Profit Margin	-11.89%	-3.39%	3.95%
Selling, General & Admin	$23.43M	$23.44M	$20.49M
YoY Change	14.31%	46.26%	157.79%
% of Gross Profit			16395.2%
Research & Development	$5.097M	$5.702M	$5.990M
YoY Change	-14.91%	28.83%	213.61%
% of Gross Profit			4792.0%
Depreciation & Amortization	$447.0K	$400.0K	$343.0K
YoY Change	30.32%	33.33%	90.56%
% of Gross Profit			274.4%
Operating Expenses	$28.52M	$29.14M	$26.48M
YoY Change	7.7%	42.49%	168.6%
Operating Profit	-$28.88M	-$29.26M	-$26.36M
YoY Change	9.56%	44.01%	178.64%
Interest Expense	$641.0K	$485.0K	$44.00K
YoY Change	1356.82%	1176.32%	120.0%
% of Operating Profit
Other Income/Expense, Net	$15.00K	$489.0K	$262.0K
YoY Change	-94.27%	136.23%	-120.79%
Pretax Income	-$28.22M	-$28.77M	-$26.05M
YoY Change	8.33%	43.06%	175.99%
Income Tax
% Of Pretax Income
Net Earnings	-$28.22M	-$28.77M	-$26.05M
YoY Change	8.33%	43.06%	175.99%
Net Earnings / Revenue	-942.65%	-805.26%	-823.16%
Basic Earnings Per Share		-$0.96
Diluted Earnings Per Share	-$0.93	-$0.96	-$876.0K
COMMON SHARES
Basic Shares Outstanding	30.21M shares	30.04M shares
Diluted Shares Outstanding		30.10M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$126.2M	$149.1M	$225.3M
YoY Change	-44.01%	-40.22%	253.18%
Cash & Equivalents	$77.80M	$95.49M	$176.9M
Short-Term Investments	$48.41M	$53.64M	$48.45M
Other Short-Term Assets	$733.0K	$643.0K	$136.0K
YoY Change	438.97%	261.24%	72.15%
Inventory	$1.757M	$1.391M	$480.0K
Prepaid Expenses
Receivables	$4.172M	$6.101M	$3.847M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$136.0M	$160.8M	$232.8M
YoY Change	-41.57%	-36.74%	248.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.375M	$4.943M	$4.549M
YoY Change	40.14%	15.09%	66.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$168.0K	$167.0K	$167.0K
YoY Change	0.6%	0.0%	0.0%
Total Long-Term Assets	$66.04M	$33.23M	$15.49M
YoY Change	326.46%	112.37%	434.33%
TOTAL ASSETS
Total Short-Term Assets	$136.0M	$160.8M	$232.8M
Total Long-Term Assets	$66.04M	$33.23M	$15.49M
Total Assets	$202.1M	$194.1M	$248.3M
YoY Change	-18.62%	-28.1%	255.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.419M	$2.997M	$2.880M
YoY Change	-16.01%	19.69%	83.09%
Accrued Expenses	$3.464M	$3.539M	$1.227M
YoY Change	182.31%	81.49%	60.81%
Deferred Revenue	$100.0K	$400.0K	$1.400M
YoY Change	-92.86%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$116.0K	$124.0K	$121.0K
YoY Change	-4.13%	-14.48%	21.0%
Total Short-Term Liabilities	$15.64M	$16.99M	$12.18M
YoY Change	28.36%	57.29%	124.53%
LONG-TERM LIABILITIES
Long-Term Debt	$53.00K	$77.00K	$136.0K
YoY Change	-61.03%	-64.35%	-32.0%
Other Long-Term Liabilities	$54.03M	$22.01M	$6.294M
YoY Change	758.48%	215.86%	949.0%
Total Long-Term Liabilities	$54.09M	$22.09M	$6.430M
YoY Change	741.15%	207.43%	703.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.64M	$16.99M	$12.18M
Total Long-Term Liabilities	$54.09M	$22.09M	$6.430M
Total Liabilities	$69.72M	$39.08M	$18.61M
YoY Change	274.63%	117.28%	134.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$323.0M	-$294.8M	-$206.4M
YoY Change	56.52%	63.51%	61.19%
Common Stock	$456.2M	$450.9M	$436.2M
YoY Change	4.58%	4.32%	129.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$132.4M	$155.0M	$229.7M
YoY Change
Total Liabilities & Shareholders Equity	$202.1M	$194.1M	$248.3M
YoY Change	-18.62%	-28.1%	255.85%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q4
OPERATING ACTIVITIES
Net Income	-$28.22M	-$28.77M	-$26.05M
YoY Change	8.33%	43.06%	175.99%
Depreciation, Depletion And Amortization	$447.0K	$400.0K	$343.0K
YoY Change	30.32%	33.33%	90.56%
Cash From Operating Activities	-$21.23M	-$24.80M	-$22.68M
YoY Change	-6.39%	55.99%	236.5%
INVESTING ACTIVITIES
Capital Expenditures	$1.933M	-$12.00K	-$1.056M
YoY Change	-283.05%	-98.33%	322.4%
Acquisitions
YoY Change
Other Investing Activities	$5.472M	-$454.0K	-$3.467M
YoY Change	-257.83%	-93.4%	33.35%
Cash From Investing Activities	$3.539M	-$466.0K	-$4.523M
YoY Change	-178.24%	-93.87%	58.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-33.00K	433.0K	25.00K
YoY Change	-232.0%	-55.41%	-99.87%
NET CHANGE
Cash From Operating Activities	-21.23M	-24.80M	-22.68M
Cash From Investing Activities	3.539M	-466.0K	-4.523M
Cash From Financing Activities	-33.00K	433.0K	25.00K
Net Change In Cash	-17.72M	-24.83M	-27.18M
YoY Change	-34.79%	10.26%	-382.22%
FREE CASH FLOW
Cash From Operating Activities	-$21.23M	-$24.80M	-$22.68M
Capital Expenditures	$1.933M	-$12.00K	-$1.056M
Free Cash Flow	-$23.16M	-$24.79M	-$21.62M
YoY Change	7.12%	63.31%	233.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001651944
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
CY2019Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.5
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38118
	dei	Entity Registrant Name EntityRegistrantName	DERMTECH, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-2870849
	dei	Entity Address Address Line1 EntityAddressAddressLine1	11099 N. Torrey Pines Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
	dei	Entity Address City Or Town EntityAddressCityOrTown	La Jolla
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92037
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	450-4222
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	DMTK
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30214705	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95492000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	176882000	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	53636000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	48449000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6101000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3847000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1391000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	480000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4212000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3166000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	160832000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	232824000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4943000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4549000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24644000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7744000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3477000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3025000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	167000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	167000	usd
CY2022Q3	us-gaap	Assets Assets	194063000	usd
CY2021Q4	us-gaap	Assets Assets	248309000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2997000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2880000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8321000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5120000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3539000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1227000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	417000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1380000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1588000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1453000	usd
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	124000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	121000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	16986000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12181000	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	20000	usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	146000	usd
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	77000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	136000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21992000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6148000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	39075000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	18611000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	24245000	usd
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30213206	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30213206	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29772922	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29772922	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	450904000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	436183000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1095000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-124000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-294824000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-206364000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	154988000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	229698000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	194063000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	248309000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3573000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3030000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11524000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8673000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	3694000	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	2898000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	10521000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	7524000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	-121000	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	132000	usd
	us-gaap	Gross Profit GrossProfit	1003000	usd
	us-gaap	Gross Profit GrossProfit	1149000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14632000	usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9826000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	45076000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5702000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4426000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18955000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10271000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8806000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6199000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26258000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17672000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	29140000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	20451000	usd
	us-gaap	Operating Expenses OperatingExpenses	90289000	usd
	us-gaap	Operating Expenses OperatingExpenses	52188000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-29261000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20319000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-89286000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-51039000	usd
CY2022Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	485000	usd
CY2021Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	38000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	700000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	107000	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4000	usd
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-169000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-126000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1350000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	489000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	207000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	826000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1243000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-28772000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-20112000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-88460000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-52282000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30096261	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30096261	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29639802	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29639802	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29969435	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29969435	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28599375	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28599375	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.96
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.96
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.95
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.95
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.83
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-28772000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-20112000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-88460000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-52282000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-230000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-971000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-7000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29002000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20122000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-89431000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52289000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	229698000	usd
CY2022Q1	dmtk	Stock Issued During Period Value Stock Options Exercised And Rsu Release StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease	40000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	12000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	515000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-570000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3894000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-30108000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	203481000	usd
CY2022Q2	dmtk	Stock Issued During Period Value Stock Options Exercised And Rsu Release StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease	0	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	10000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-171000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4837000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-29580000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	178577000	usd
CY2022Q3	dmtk	Stock Issued During Period Value Stock Options Exercised And Rsu Release StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease	0	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	477000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-230000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4936000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-28772000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	154988000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	61840000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	134582000	usd
CY2021Q1	dmtk	Stock Issued During Period Value Stock Options Exercised And Rsu Release StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease	408000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	72081000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	392000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2172000	usd
CY2021Q1	dmtk	Reclassification Of Warrant Liability Due To Private Spac Warrants Not Held By Original Holder ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder	411000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-15068000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	256827000	usd
CY2021Q2	dmtk	Stock Issued During Period Value Stock Options Exercised And Rsu Release StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease	188000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	700000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	23836000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	5000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-6000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3538000	usd
CY2021Q2	dmtk	Reclassification Of Warrant Liability Due To Private Spac Warrants Not Held By Original Holder ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder	23000	usd
CY2021Q2	dmtk	Reclassification Of Warrant Liability Due To Private Spac Warrants Not Held By Original Holder ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder	23000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-17102000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	267309000	usd
CY2021Q3	dmtk	Stock Issued During Period Value Stock Options Exercised And Rsu Release StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease	81000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	343000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	574000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3736000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-20112000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	251921000	usd
	us-gaap	Profit Loss ProfitLoss	-88460000	usd
	us-gaap	Profit Loss ProfitLoss	-52282000	usd
	us-gaap	Depreciation Depreciation	1187000	usd
	us-gaap	Depreciation Depreciation	654000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-126000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1350000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1788000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	909000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	13667000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9446000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-328000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-463000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-350000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-13000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2254000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1339000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	911000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	320000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1046000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	104000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2709000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1130000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	955000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1525000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3201000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1389000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74030000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39426000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	26420000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	25150000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	350000	usd
	dmtk	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	19934000	usd
	dmtk	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	18475000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1372000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1664000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7858000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7989000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	22000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	70271000	usd
	dmtk	Proceeds From Release Of Rs Us And Stock Options Exercised ProceedsFromReleaseOfRSUsAndStockOptionsExercised	40000	usd
	dmtk	Proceeds From Release Of Rs Us And Stock Options Exercised ProceedsFromReleaseOfRSUsAndStockOptionsExercised	677000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	992000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	966000	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	104000	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	80000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	950000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	230252000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-80938000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	182837000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	179907000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24248000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	98969000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	207085000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95492000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	204061000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	3477000	usd
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	3024000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98969000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	207085000	usd
	us-gaap	Interest Paid Net InterestPaidNet	10000	usd
	us-gaap	Interest Paid Net InterestPaidNet	13000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	511000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	462000	usd
	dmtk	Reclassification Of Warrant Liability Due To Private Spac Warrants Not Held By Original Holder ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder	0	usd
	dmtk	Reclassification Of Warrant Liability Due To Private Spac Warrants Not Held By Original Holder ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder	434000	usd
	dmtk	Cashless Exercise Of Common Stock Warrants CashlessExerciseOfCommonStockWarrants	0	usd
	dmtk	Cashless Exercise Of Common Stock Warrants CashlessExerciseOfCommonStockWarrants	2158000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18688000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9071000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	48000	usd
	us-gaap	Depreciation Depreciation	700000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	105000	usd
	dmtk	Change In Unrealized Gain Loss On Available For Sale Marketable Securities ChangeInUnrealizedGainLossOnAvailableForSaleMarketableSecurities	-971000	usd
	dmtk	Change In Unrealized Gain Loss On Available For Sale Marketable Securities ChangeInUnrealizedGainLossOnAvailableForSaleMarketableSecurities	-7000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of Operations <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including genomic tests to facilitate the diagnosis of dermatologic conditions including melanoma. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) to collect biological information for commercial applications in the medical diagnostic field.</span></div>The ongoing COVID-19 pandemic has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company is considered an essential business due to the importance of early melanoma detection, which has allowed the Company’s CLIA laboratory to remain fully operational. The Company implemented additional safety measures in accordance with Centers for Disease Control and Prevention, Occupational Safety and Health Administration and other guidance within its CLIA laboratory operations. Additionally, and during this time, the Company transitioned administrative functions to predominantly remote work. The pandemic reduced patient access to clinician offices for in-person testing and reduced access by the Company's sales force for in-office sales calls, which negatively impacted the volume of billable samples. The level and nature of the disruption caused by COVID-19 is unpredictable, may be cyclical, and long-lasting and may again in the future, adversely affect the Company's operating results.
	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to assay revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates.
CY2022Q3	us-gaap	Depreciation Depreciation	400000	usd
CY2021Q3	us-gaap	Depreciation Depreciation	300000	usd
	us-gaap	Depreciation Depreciation	1200000	usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-100000	usd
CY2021Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-400000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-13000	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2021Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. As of September 30, 2022, the Company maintained $64.6 million in a sweep account, which maintains cash balances throughout various interest-bearing bank accounts under the $250,000 insurance limit provided by the Federal Deposit Insurance Corporation for one federally insured financial institution.
CY2022Q3	us-gaap	Deposits Money Market Deposits DepositsMoneyMarketDeposits	64600000	usd
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	300000	usd
	dmtk	Number Of Revenue Streams NumberOfRevenueStreams	2	revenuestream
CY2022Q3	dmtk	Revenue Performance Obligation Satisfied Variable Consideration Update Increase Decrease In Revenue RevenuePerformanceObligationSatisfiedVariableConsiderationUpdateIncreaseDecreaseInRevenue	-500000	usd
	dmtk	Revenue Performance Obligation Satisfied Variable Consideration Update Increase Decrease In Revenue RevenuePerformanceObligationSatisfiedVariableConsiderationUpdateIncreaseDecreaseInRevenue	-500000	usd
CY2021Q3	dmtk	Revenue Performance Obligation Satisfied Variable Consideration Update Increase Decrease In Revenue RevenuePerformanceObligationSatisfiedVariableConsiderationUpdateIncreaseDecreaseInRevenue	18000	usd
	dmtk	Revenue Performance Obligation Satisfied Variable Consideration Update Increase Decrease In Revenue RevenuePerformanceObligationSatisfiedVariableConsiderationUpdateIncreaseDecreaseInRevenue	100000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3573000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3030000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11524000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8673000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	400000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1400000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract	900000	usd
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	54731000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1098000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	53636000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	48573000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	125000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	48449000	usd
CY2022Q3	dmtk	Estimated Market Value Of Debt Securities With Contractual Maturities Of Less Than12 Months EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months	38300000	usd
CY2022Q3	dmtk	Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To21 Months EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo21Months	15300000	usd
CY2021Q4	dmtk	Estimated Market Value Of Debt Securities With Contractual Maturities Of Less Than12 Months EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months	21200000	usd
CY2021Q4	dmtk	Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To21 Months EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo21Months	27200000	usd
CY2021Q4	dmtk	Credit Losses CreditLosses	0	usd
CY2022Q3	dmtk	Credit Losses CreditLosses	0	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	1547000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1801000	usd
CY2022Q3	dmtk	Prepaid Trade Shows Current PrepaidTradeShowsCurrent	693000	usd
CY2021Q4	dmtk	Prepaid Trade Shows Current PrepaidTradeShowsCurrent	440000	usd
CY2022Q3	dmtk	Prepaid Software Fees PrepaidSoftwareFees	1038000	usd
CY2021Q4	dmtk	Prepaid Software Fees PrepaidSoftwareFees	551000	usd
CY2022Q3	dmtk	Prepaid Employee Compensation PrepaidEmployeeCompensation	291000	usd
CY2021Q4	dmtk	Prepaid Employee Compensation PrepaidEmployeeCompensation	238000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	643000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	136000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4212000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3166000	usd
CY2022Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	4744000	usd
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	4805000	usd
CY2022Q3	dmtk	Computer Equipment Gross ComputerEquipmentGross	356000	usd
CY2021Q4	dmtk	Computer Equipment Gross ComputerEquipmentGross	171000	usd
CY2022Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	807000	usd
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	124000	usd
CY2022Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1009000	usd
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1074000	usd
CY2022Q3	us-gaap	Construction In Progress Gross ConstructionInProgressGross	585000	usd
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	0	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7501000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6174000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2558000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1625000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4943000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4549000	usd
CY2022Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1790000	usd
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1245000	usd
CY2022Q3	dmtk	Accrued Bonus And Deferred Compensation Current AccruedBonusAndDeferredCompensationCurrent	6531000	usd
CY2021Q4	dmtk	Accrued Bonus And Deferred Compensation Current AccruedBonusAndDeferredCompensationCurrent	3875000	usd
CY2021Q1	dmtk	Underwriters Grant Period Option UnderwritersGrantPeriodOption	P30D
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8321000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5120000	usd
CY2022Q3	dmtk	Accrued Consulting Services Current AccruedConsultingServicesCurrent	1173000	usd
CY2021Q4	dmtk	Accrued Consulting Services Current AccruedConsultingServicesCurrent	775000	usd
CY2022Q3	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	926000	usd
CY2021Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	0	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1440000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	452000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3539000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1227000	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4237288	shares
CY2021Q1	dmtk	Stock Purchased By Underwriters Pursuant To Option Granted StockPurchasedByUnderwritersPursuantToOptionGranted	635593	shares
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4872881	shares
CY2021Q1	dmtk	Stock Purchased By Underwriters Pursuant To Option Granted StockPurchasedByUnderwritersPursuantToOptionGranted	635593	shares
CY2021Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	29.50
CY2021Q1	dmtk	Gross Proceeds From Offering Before Deducting Underwriting Discounts And Commissions And Other Offering Expenses GrossProceedsFromOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses	143700000	usd
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	134600000	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4936000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3736000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13667000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9446000	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	49100000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M10D
CY2022Q3	dmtk	Duration Of Offering Period DurationOfOfferingPeriod	P24M
CY2022Q3	dmtk	Number Of Six Month Purchase Periods NumberOfSixMonthPurchasePeriods	4	period
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7440	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4591	shares
	dmtk	Percentage Of Useful Lives Of Assets PercentageOfUsefulLivesOfAssets	0.75
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	215000	usd
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	274000	usd
CY2022Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	14000	usd
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	17000	usd
CY2022Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	201000	usd
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	257000	usd
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	124000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	121000	usd
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	77000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	136000	usd
CY2022Q3	dmtk	Number Of Improvement Phases NumberOfImprovementPhases	4	phase
CY2022Q3	dmtk	Tenant Improvement Allowance TenantImprovementAllowance	300000	usd
CY2022Q3	dmtk	Lessee Operating Lease Number Of Renewal Terms LesseeOperatingLeaseNumberOfRenewalTerms	1	period
CY2022Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2021Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P28M
CY2021Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0404
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3100000	usd
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2800000	usd
CY2021Q1	dmtk	Tenant Improvement Allowance TenantImprovementAllowance	300000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1056000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	379000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	2724000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1023000	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	188000	usd
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	171000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	680000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	486000	usd
CY2022Q3	dmtk	Operating Lease Costs OperatingLeaseCosts	1244000	usd
CY2021Q3	dmtk	Operating Lease Costs OperatingLeaseCosts	550000	usd
	dmtk	Operating Lease Costs OperatingLeaseCosts	3404000	usd
	dmtk	Operating Lease Costs OperatingLeaseCosts	1509000	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	21000	usd
CY2021Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	17000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	62000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	53000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	105000	usd
CY2022Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000	usd
CY2021Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	10000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	13000	usd
CY2022Q3	dmtk	Finance Lease Cost FinanceLeaseCost	24000	usd
CY2021Q3	dmtk	Finance Lease Cost FinanceLeaseCost	22000	usd
	dmtk	Finance Lease Cost FinanceLeaseCost	72000	usd
	dmtk	Finance Lease Cost FinanceLeaseCost	66000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	3621000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1516000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	10000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	13000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	104000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	80000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18688000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9071000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	48000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y3D
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y3M29D
CY2022Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M13D
CY2021Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M1D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0644
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0578
CY2022Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0581
CY2021Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0576
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	791000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2948000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2774000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2853000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2934000	usd
CY2022Q3	dmtk	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	20612000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	32912000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	25000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	133000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	19000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	19000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	15000	usd
CY2022Q3	dmtk	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	4000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	215000	usd
CY2022Q3	dmtk	Operating And Finance Lease Liability Payments Remainder Of Fiscal Year OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	816000	usd
CY2022Q3	dmtk	Operating And Finance Lease Liability Payments Due Next Twelve Months OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3081000	usd
CY2022Q3	dmtk	Operating And Finance Lease Liability Payments Due Year Two OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo	2793000	usd
CY2022Q3	dmtk	Operating And Finance Lease Liability Payments Due Year Three OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree	2872000	usd
CY2022Q3	dmtk	Operating And Finance Lease Liability Payments Due Year Four OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour	2949000	usd
CY2022Q3	dmtk	Operating And Finance Lease Liability Payments Due Thereafter OperatingAndFinanceLeaseLiabilityPaymentsDueThereafter	20616000	usd
CY2022Q3	dmtk	Operating And Finance Lease Liability Payments Due OperatingAndFinanceLeaseLiabilityPaymentsDue	33127000	usd
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	usd
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	usd

Files In Submission

Name	View Source	Status
0001651944-22-000054-index-headers.html	Edgar Link	pending
0001651944-22-000054-index.html	Edgar Link	pending
0001651944-22-000054.txt	Edgar Link	pending
0001651944-22-000054-xbrl.zip	Edgar Link	pending
dmtk-20220930.htm	Edgar Link	pending
dmtk-20220930.xsd	Edgar Link	pending
dmtk-20220930xex311.htm	Edgar Link	pending
dmtk-20220930xex312.htm	Edgar Link	pending
dmtk-20220930xex321.htm	Edgar Link	pending
ex103dermtech-amendedandre.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
dmtk-20220930_cal.xml	Edgar Link	unprocessable
dmtk-20220930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dmtk-20220930_lab.xml	Edgar Link	unprocessable
dmtk-20220930_pre.xml	Edgar Link	unprocessable
dmtk-20220930_htm.xml	Edgar Link	completed
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DMTKQ
DermTech Inc Stock $dmtkq

2022 Q4 Form 10-Q Financial Statement

#000165194422000054 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DMTKQ DermTech Inc Stock $dmtkq

2022 Q4 Form 10-Q Financial Statement

#000165194422000054 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DMTKQ
DermTech Inc Stock $dmtkq